Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetylsalicylic acid + clopidogrel + ticagrelor
- Development stage
- Unknown
- Lead developer
- V.A. Almazov Federal Center for Heart, Blood and Endocrinology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a regimen of antiplatelet agents—acetylsalicylic acid (aspirin), clopidogrel, and ticagrelor—investigated by the Almazov Federal North-West Medical Research Centre for the management of patients undergoing endovascular treatment for intracranial aneurysms. Specifically, the research (such as the DERIVO study) evaluates different combinations and durations of these therapies, including dual antiplatelet therapy (DAPT) consisting of aspirin plus either clopidogrel or ticagrelor, compared against monotherapy. Acetylsalicylic acid acts as a COX-1 inhibitor, while clopidogrel and ticagrelor are P2Y12 receptor antagonists, collectively working to prevent thromboembolic complications associated with flow-diverter stents like the DERIVO device.
- Brand names
- Brilinta
- Other names
- ASA + clopidogrel + ticagrelorAspirin + clopidogrel + ticagrelor
02
Targets
P2Y12 (Purinergic P2Y12 receptor)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on acetylsalicylic acid + clopidogrel + ticagrelor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetylsalicylic acid + clopidogrel + ticagrelor.